Vascular surgeons perform procedures interventional cardiologists and interventional radiologists do not do—so why not make sure they are part of every heart team conversation?
The Center for Medicare and Medicaid Innovation (CMMI) has tested nearly 40 APMs, of which only two turned out to be successful, which does not bode well for meeting a 2030 deadline to transition to value-based payments.
Afnan Tariq, MD, discusses early data on a passive, device-agnostic AI platform for heart failure monitoring. “When clinicians are empowered with insights and able to act earlier, you're able to have a durable impact," he said.
Deepak Bhatt, MD, believes bentracimab could be a game-changer if it gains approval. "I think it's the sort of drug that every emergency room and ICU would have to stock," he said. "A cardiac care unit would have to stock a couple of doses, as would every cath lab."
RBMA board member Kit Crancer offers an update on Medicare reform and advocacy in Congress and how medical societies may be able to get more traction in state legislatures.
Raj Makkar, MD, Cedars-Sinai, explains the late-breaking data from the Align-AR trial on the first 500 patients treated for aortic regurgitation using the Jena Valve TAVR device.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.
ACC Immediate Past President Cathie Biga spoke to Cardiovascular Business about some of the challenges healthcare faces in the wake of mass layoffs and significant funding cuts put in place by the Trump administration.
